{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:36:56Z","timestamp":1793144216968,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bbmt.2020.02.012","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:53:36Z","timestamp":1582246416000},"page":"1071-1076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery"],"prefix":"10.1016","volume":"26","author":[{"given":"Victoria","family":"Gutgarts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly A.","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josel D.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar A.","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer","family":"Sathick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.02.012_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0003","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0005","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0007","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0008","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0009","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0010","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0011","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0012","doi-asserted-by":"crossref","unstructured":"Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies[e-pub ahead of print]. Biol Blood Marrow Transplant. doi: 10.1016\/j.bbmt.2019.11.027, accessed December 2019.","DOI":"10.1016\/j.bbmt.2019.11.027"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0013","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.bbmt.2019.11.013","article-title":"Late psychiatric and neurocognitive effects of chimeric antigen receptor T cell therapy warrant further investigation","volume":"26","author":"Moyo","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0014","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.bbmt.2019.10.020","article-title":"Late events after CD-19 CAR-T treatment","volume":"26","author":"Hossain","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0016","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.bbmt.2019.01.001","article-title":"Harmonizing immune effector toxicity reporting","volume":"25","author":"Heslop","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0018","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0019","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","volume":"2","author":"Jain","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0021","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0022","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0023","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0024","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0025","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0026","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2215\/CJN.03110410","article-title":"The CKD-EPI equation for estimating GFR from serum creatinine: real improvement or more of the same?","volume":"5","author":"Rule","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0027","unstructured":"KDIGO: Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury. March 2012. Available at: https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-AKI-Guideline-English.pdf. Accessed August 2019."},{"key":"10.1016\/j.bbmt.2020.02.012_bib0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0029","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/bmt.2016.343","article-title":"Long-term renal survival in patients undergoing T cell-depleted versus conventional hematopoietic stem cell transplants","volume":"52","author":"Glezerman","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0031","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal complications of hematopoietic-cell transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0032","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/bmt.2009.377","article-title":"A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT","volume":"45","author":"Ando","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0033","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2215\/CJN.06470614","article-title":"Estimating GFR in adult patients with hematopoietic cell transplant: comparison of estimating equations with an iohexol reference standard","volume":"10","author":"Hingorani","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0034","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJMra032401","article-title":"Acute renal failure and sepsis","volume":"351","author":"Schrier","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0035","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Ya\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0036","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0037","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0038","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0039","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cells toxicities grading systems: application of ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/1995-705X.125926","article-title":"Contrast-induced nephropathy","volume":"14","author":"Mohammed","year":"2013","journal-title":"Heart Views"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0041","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.012_bib0042","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/CN109872","article-title":"Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells","volume":"93","author":"Dixon","year":"2020","journal-title":"Clin Nephrol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:45Z","timestamp":1761059385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120300975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1083879120300975"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}